抄録
Purpose of developing the guidelines: The first guidelines for diagnosis and treatment of 21-hydroxylase deficiency (21-OHD) were published as a diagnostic handbook in Japan in 1989, with a focus on patients with severe disease. The “Guidelines for Treatment of Congenital Adrenal Hyperplasia (21-Hydroxylase Deficiency) Found in Neonatal Mass Screening (1999 revision)” published in 1999 were revised to include 21-OHD patients with very mild or no clinical symptoms. Accumulation of cases and experience has subsequently improved diagnosis and treatment of the disease. Based on these findings, the Mass Screening Committee of the Japanese Society for Pediatric Endocrinology further revised the guidelines for diagnosis and treatment. Target disease/conditions: 21-hydroxylase deficiency. Users of the guidelines: Physician specialists in pediatric endocrinology, pediatric specialists, referring pediatric practitioners, general physicians; and patients.
| 本文言語 | 英語 |
|---|---|
| ページ（範囲） | 77-105 |
| ページ数 | 29 |
| ジャーナル | Clinical Pediatric Endocrinology |
| 巻 | 24 |
| 号 | 3 |
| DOI | |
| 出版ステータス | 出版済み - 18-07-2015 |
| 外部発表 | はい |
All Science Journal Classification (ASJC) codes
- 小児科学、周産期医学および子どもの健康
- 内分泌学、糖尿病および代謝内科学
- 内分泌学
UN SDG
この成果は、次の持続可能な開発目標に貢献しています
